Immuno-Oncology Clinical Trials Update: Oncolytic Viruses Issue 5 February 2017
|
|
- Daniella Copeland
- 5 years ago
- Views:
Transcription
1 Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Oncolytic Viruses Issue 5 February 2017
2 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY series is to provide: A regularly updated database of CLINICAL TRIALS in the key areas of the evolving immuno-oncology (I-O) market This service is COMPLIMENTARY. It is based on clinical trials from We recognize that the information in this database is not 100% accurate as timing and registration details for specific trials may be out of date. In addition, it is not required for Phase 1 drug and biologic trials to be recorded. However, in aggregate, this information provides value due to the large number of clinical trials analyzed. This service lists all relevant clinical trials in the following areas of the I-O market, together with overall top-line analysis. Each area will be covered and updated around twice a year: 1. CAR cells (chimeric antigen receptor cells, or genetically-engineered immune cells) Oct Bispecific antibodies Nov Checkpoint inhibitors Anti-PD-1/PD-L1 Dec Checkpoint inhibitors Others Jan Oncolytic viruses Feb ADCs (antibody-drug conjugates) 7. Immune activators or stimulators and therapeutic vaccines This series is produced by EMC Analytics Group. We are specialists in competitive strategy and help clients understand the competitive forces impacting either their product development or commercial plans. If you would like ADDITIONAL DETAILS on any area of the I-O market, or other drug markets, please feel free to contact: Mike Ratcliffe EMC Managing Director mratcliffe@emcanalytics.com +1 (508)
3 Oncolytic viruses are an emerging modality for combination treatments Imlygic (talimogene laherparepvec or T-VEC) from Amgen is the first approved oncolytic viral therapy in the U.S. FDA approved Imlygic in October 2015 for local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after surgery Average price of $65,000 per treatment course OPTiMtrial in advanced [Stage IIIB-IV] melanoma showed higher efficacy for Imlygic vs subcutaneous GM-CSF: Overall response rate of 26.4% vs. 5.7% Durable response rate of 16.3% vs. 2.1% However, the median overall survival increase [23.3. vs months] was not considered significant Imlygic showed low toxicity: the only grade > 3 adverse event was cellulitis in just 2.1% of patients Despite modest clinical efficacy as monotherapies, oncolytic viruses (OVs) induce anti-cancer immune cells and several combination tests with other agents are ongoing Checkpoint inhibitors Combination has shown increased efficacy compared to virus or checkpoint inhibitor alone in animal models Adding checkpoint inhibitors makes sense to prevent exhaustion and expand the newly generated tumor killer cells Chemos and radiotherapy Induces immunogenic cell death, leading to release of new tumor antigens and enhanced tumor immune responses The combination has shown synergy in in vitro and in vivo models Given the very low toxicity of oncolytic viruses, no new adverse events are expected Although Imlygic and several other current OVs are delivered loco-regionally, future OVs may be designed for systemic delivery to enable them to reach all sites of tumor growth in metastatic disease Challenges: For clinical translation, manufacturing processes, development and regulatory approval paths will need to be individualized for each OV Development of toxicity models, increase of viral yields, commercial scale purification, long-term stability formulations, bioavailability, tumor resistance to the virus, and the host immune response against the OV are challenges to overcome OV combination therapies are promising in terms of efficacy and likely to be increasingly tested in the near future, but challenges include selection of virus, tumor type, combination agent[s], regimen, and cost 3
4 Oncolytic Viruses in Clinical Trials Sponsor/Collaborators Therapy Base Virus Commercial Amgen Imlygic (talimogene laherparepvec,t-vec, OncoVex GM-CSF ) herpes simplex virus 1 (HSV-1) Cold Genesys CG0070 adenovirus DNAtrix DNX2401 adenovirus serotype 5 Genelux GL-ONC1 vaccinia virus (Lister strain) Hadassah Medical Org MTH-68H Newcastle disease virus Institut Catal d'oncologia ICOVIR-5 adenovirus Lokon Pharma LOAd703 adenovirus MediGene G207 herpes simplex virus (HSV-1) Oncolys Telomelysin (OBP-301) adenovirus Oncolytics Reolysin reovirus Oryx H-1PV parvovirus PsiOxus Therapeutics Enadenotucirev adenovirus Shanghai Sunway Biotech H101 adenovirus SillaJen (Jennerex) Transgene Pexa-Vec (JX-594) vaccina virus Takara Bio TBI-1401 (HF10) herpes simplex virus (HSV-1) Targovax (Oncos Therapeutics) ONCOS-102 (CGTG-102) adenovirus Tocagen Toca 511 (vocimagene amiretrorepvec) nonlytic retroviral replicating vector Turnstone Biologics Chiltern International Ad-MAGEA3 MG1-MAGEA3 Maraba virus VCN Biosciences VCN-01 adenovirus Viralytics CAVATAK (Coxsackievirus A21, CVA21) coxsackie virus Virttu Biologics HSV1716 herpes simplex virus (HSV-1) Academic Benjamin Movsas, M.D. Henry Ford Health System Ad5-yCD/mutTKSR39rep-ADP adenovirus Darell D. Bigner, MD Solving Kids Cancer Duke Univ PVSRIPO recombinant polio/rhinovirus Erasmus MC VU Univ Medical Center delta-24-rgd adenovirus adenovirus Jenny C. Chang, MD Merck Methodist Hos System (Ark Therapeutics) ADV/HSV-tk adenovirus Mayo Clinic MV-NIS measles virus (Edmonston strain) Univ of AK MV-NIS measles virus (Edmonston strain) NewGenPharm Theragene, Ad5-yCD/mutTKSR39rep-ADP adenovirus 4
5 Major focus in brain cancer Unlike other I-O therapies, research on oncolytic viruses has a strong focus on brain cancer Brain cancer, glioma, glioblastoma, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma As with other I-O therapies, a wide range of solid tumors are being investigated, but fewer trials with blood-based tumors are seen with OVs compared to other I-O technologies Industry sponsors are focusing more on specific cancer types: Amgen melanoma and to a less extent breast cancer Tocagen brain cancers Viralytics bladder, brain, and NSCLC The NCI, often in partnership with the Mayo Clinic, is researching OVs in a wide range of solid tumors Breakdown by Cancer Type (# = 159) (includes counts of multiple indications in the same trial) Brain Melanoma Lung Sancoma Bladder Pancreas Breast Ovarian Carcinoma Lymphoma CRC H&N Meso HCC Fallopian CNS Solid tumors - general Other - specific cancers number of trials 5
6 U.S. industry sponsors dominate the clinical market Roughly 10% of all trials has progressed to Phase 2/3 or Phase 3 (6 trials) with half still in Phase 1 Industry sponsors dominate this area of the I-O market, either running the trial themselves or partnering with academia Amgen has over 20% of the trials and is by far the largest industry sponsor All are with Imlygic The NCI also has nearly 20% of the trials and is by far the largest non-industry sponsor It is partnering with the Mayo Clinic for roughly half of its trials and its oncolytic measles virus Breakdown by Phase (# = 82) P1 P1/2 P2 P3 Breakdown by Type of Sponsor (# = 82) Industry Industry/Other Other Nearly three quarters of all trial are through U.S. sponsors Amgen is the major U.S. industry sponsor with Imlygic Viralytics (Australia) is the major non-u.s. industry sponsor with CAVATAK, a oncolytic common cold virus All but one non-industry sponsored trial is U.S.-based Breakdown by Location of Sponsor (# = 82) USA Europe RoW 6
7 7
8 8
9 9
10 Backgrounder Oncolytic viruses in cancer treatment Oncolytic viruses (Ovs) are viruses that selectively replicate in and kill cancer cells by lysing them Because the antiviral defense pathways are impaired in tumor cells, OVs selectively replicate in such cells, sparing healthy cells In addition to lysing tumor cells, OVs liberate tumor antigens and induce immune responses against cancer cells OVs can be genetically engineered to Improve tumor selectivity and safety Tumor killing activity and efficacy Express immunostimulatory proteins, which may increase the systemic killing of OV-uninfected tumor cells The incidence of severe [Grade> 3] side effects caused by OVs is generally very low In addition to inducing anti cancer immune cells, OVs can decrease the immunosuppression of the tumor microenvironment by blocking or depleting regulatory T cells (T-regs) or myeloid-derived suppressor cells (MDSCs), and can lyse cancer stem cells thereby constituting a promising approach against cancer drug resistance and relapse 10
Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationLimitations of Use: Imlygic has not been shown to improve overall survival or have an effect on visceral metastases (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.66 Subject: Imlygic Page: 1 of 5 Last Review Date: June 22, 2017 Imlygic Description Imlygic (talimogene
More informationFor personal use only
Cancer killing viruses Oncolytic Virotherapeutics Bryan Dulhunty Managing Director Bell Potter Life Sciences Conference Building a Global Profile May 2102 bryan.dulhunty@viralytics.com www.viralytics.com
More informationConcept of oncolytic virotherapyclinical
Concept of oncolytic virotherapyclinical implementation Simona Donina A. Kirchenstein Institute of Microbiology and Virology, Riga Stradiņš University Riga East University Hospital 4.04.2014. Timeline
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationCopyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview
Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview Toca 511, delivers CD prodrug activator gene selectively to cancer cells Regulatory genes Structural RRV genes CD gene Regulatory genes Toca
More informationTwo roads for oncolytic immunotherapy development
Kaufman and Bommareddy Journal for ImmunoTherapy of Cancer (2019) 7:26 https://doi.org/10.1186/s40425-019-0515-2 COMMENTARY Two roads for oncolytic immunotherapy development Howard L. Kaufman 1,2* and
More informationCoxsackievirus A21 as an oncolytic agent for the control of human cancer
Coxsackievirus A21 as an oncolytic agent for the control of human cancer Dr Gough G. Au PhD Conjoint Research Fellow The University of Newcastle Australia Viralytics Ltd. Viruses can be used to treat cancer
More informationOncolytic viruses for cancer treatment
Oncolytic viruses for cancer treatment Interdisciplinary Technical Journal Club: Special Series on Laboratory Animal Science Dr. Katrin Frauenknecht Institute of Neuropathology University Hospital Zurich
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationOncolytic viruses: a new class of immunotherapy drugs
CANCER IMMUNOTHERAPY Oncolytic viruses: a new class of immunotherapy drugs Howard L. Kaufman, Frederick J. Kohlhapp and Andrew Zloza Abstract Oncolytic viruses represent a new class of therapeutic agents
More informationVirus-based immunotherapies to transform the fight against cancers and infectious diseases. March 21, 2018 FY Results 2017 & Business update
Virus-based immunotherapies to transform the fight against cancers and infectious diseases March 21, 2018 FY Results 2017 & Business update Disclaimer This presentation contains forward-looking statements,
More informationDouglas Jolly Executive VP R&D Tocagen Inc.
REPLICATING RETROVIRUSES FOR MANIPULATION OF THE TUMOR IMMUNE ECOSYSTEM: PRECLINICAL AND CLINICAL OUTCOMES. Douglas Jolly Executive VP R&D Tocagen Inc. PEGS 2018 IT Track Boston May 1 2018 Outline Phase
More informationCANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY
CANCER VACCINES THE NEXT WAVE IN IMMUNO-ONCOLOGY Peter Skorpil VP Business Development peter.skorpil@targovax.com Cutting Edge Oslo 2016-10-18 www.targovax.com 1 Important notice and disclaimer This report
More informationExperimental Therapeutics I
Experimental Therapeutics I Mary Hitt 5142 Katz Group Centre mhitt@ualberta.ca; or Mary.Hitt@albertahealthservices.ca 1 Specific Topics for Today Preclinical and clinical testing Gene therapy Nonviral
More informationAmy Lin, Ph.D. November 14, 2018
PD L1 checkpoint blockade using a single chain variable fragment targeting PD L1 delivered by retroviral replicating vector (Toca 521) enhances anti tumor effect in murine cancer models Amy Lin, Ph.D.
More informationCBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology
CBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology Peter Bross, MD Office of Cellular, Tissue and Gene Therapies, CBER FDA IOM Policy Issues in the Clinical Development
More informationDr. Bernard Huber CEO. Bio-Europe
Dr. Bernard Huber CEO Bio-Europe 2015 1 ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany ORYX bridges
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationTalimogene Laherparepvec (T-VEC) at the SCCA: an update
Talimogene Laherparepvec (T-VEC) at the SCCA: an update Jennifer M. Gardner, MD Assistant Professor, Division of Dermatology University of Washington jen1110@uw.edu Northwest Melanoma Symposium: Science
More informationIntravenous Delivery of Toca 511 in Patients With High Grade Glioma Results in Quantifiable Expression of Cytosine Deaminase in Tumor Tissue
Intravenous Delivery of Toca 511 in Patients With High Grade Glioma Results in Quantifiable Expression of Cytosine Deaminase in Tumor Tissue Tobias Walbert, 1 Daniela Bota, 2 Michael A Vogelbaum, 3 Steven
More informationViewpoint from a health care professional
Viewpoint from a health care professional Christoph Hoeller Skin Cancer Center at the Department of Dermatology Medical University of Vienna Austria Certified Skin Tumor Center The fifth annual regulatory
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationPioneering vaccines that transform lives.
Pioneering vaccines that transform lives. Immunomic Therapeutics, Inc. LAMP-Vax for Glioblastoma: CMV-LAMP-Vax Executive Summary Executive Summary pp65-lamp-vax First Line Therapy for Glioblastoma Multiforme
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationImmuno-Oncology: Perspectives on Current Therapies & Future Developments
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/immuno-oncology-perspectives-currenttherapies-future-developments/9502/
More informationOncolytic virus immunotherapy: future prospects for oncology
Raja et al. Journal for ImmunoTherapy of Cancer (2018) 6:140 https://doi.org/10.1186/s40425-018-0458-z REVIEW Open Access Oncolytic virus immunotherapy: future prospects for oncology Junaid Raja 1, Johannes
More information2016 ONCOLYTIC VIRUS IMMUNOTHERAPY Part of CHI s
MEETING REPORT: 2016 ONCOLYTIC VIRUS IMMUNOTHERAPY Part of CHI s www.immuno-oncologysummit.com By Cole Peters and Fares Nigim, M.D. from Mass General Hospital - Harvard Medical School Cambridge Healthtech
More informationOncolytic viruses for cancer treatment
2009 3 4 1 Journal of Microbes and Infection, March 2009, Vol. 4, No. 1 35,, 200040 :,, : ; ; Oncolytic viruses for cancer treatment HOU Jian-Gang, DING Qiang Department of Urology, Huashan Hospital, Fudan
More informationToca 511 (vocimagene amiretrorepvec) Retroviral replicating vector that carries a prodrug activator enzyme
TOCA 511 & TOCA FC: EVALUATION OF DURABLE RESPONSE RATE IN THE POST-RESECTION SETTING AND ASSOCIATION WITH SURVIVAL IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA Cloughesy TF 1, Landolfi J 2, Vogelbaum
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationDurable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics. Timothy Cloughesy, MD University of California, Los Angeles
Durable Response Rate in High Grade Glioma: an Emerging Endpoint for Immunotherapeutics Timothy Cloughesy, MD University of California, Los Angeles Disclosure 2 FDA Endpoints for the Approval of Cancer
More informationSociety for Immunotherapy of Cancer (SITC)
Society for Immunotherapy of Cancer (SITC) Oncolytic Viruses and Their Application to Cancer Immunotherapy Ding Wang, MD, PhD Josephine Ford Cancer Institute Advances in Cancer Immunotherapy - Michigan
More informationDurable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment
Durable Responses Observed in IDH1 Wildtype and Mutant Recurrent High Grade Glioma with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S
More informationOncolytic Viruses: Reovirus
T S X : O N C N A S D A Q : O N C Y International Society for Biological Therapy of Cancer 2008 Oncology Biologics Development Primer Oncolytic Viruses: Reovirus REOLYSIN - mode of action REOLYSIN contains
More informationOncolytic virus strategy
Oncolytic viruses Oncolytic virus strategy normal tumor NO replication replication survival lysis Oncolytic virus strategy Mechanisms of tumor selectivity of several, some of them naturally, oncolytic
More informationViruses and cancer: Should we be more afraid?
Viruses and cancer: Should we be more afraid? Viruses and cancer: Should we be more afraid? During the past 30 years it has become exceedingly clear that several viruses play significant roles in the development
More informationORYX Translational Medicine. Dr. Dr. Sven Rohmann/ CBDO
ORYX Translational Medicine Dr. Dr. Sven Rohmann/ CBDO ORYX Overview Ø ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany
More informationVirus-based immunotherapies to transform the fight against cancers and infectious diseases. September 2018 First Half 2018 & Business Update
Virus-based immunotherapies to transform the fight against cancers and infectious diseases September 2018 First Half 2018 & Business Update Disclaimer This presentation contains forward-looking statements,
More informationORYX Translational Medicine. Dr. Bernard Huber / CEO
ORYX Translational Medicine Dr. Bernard Huber / CEO BIO International Convention June 2016 ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007
More informationORYX Translational Medicine. Dr. Bernard Huber/ CEO
ORYX Translational Medicine Dr. Bernard Huber/ CEO ORYX Overview ORYX GmbH & Co. KG (ORYX) is a privately held company for translational oncology founded in 2007 and located in Baldham/Munich, Germany
More informationOncolytic Immunotherapy: A Local and Systemic Antitumor Approach
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response
More informationA NEW FRONTIER IN IMMUNO-ONCOLOGY
A NEW FRONTIER IN IMMUNO-ONCOLOGY Proactive One2One Forum London, March 8 th 2018 Dr Richard Goodfellow LSE: SCLP.L CLINICAL STAGE IMMUNO-ONCOLOGY COMPANY Scancell is developing innovative immunotherapies
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationProduct: Talimogene Laherparepvec Clinical Study Report: Date: 31 October 2018 Page 1
Date: 31 October 2018 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Imlygic Name of Active Ingredient: Talimogene laherparepvec Title of Study: A Phase
More informationDurable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment
Durable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S 2, Carter B 6, Chen
More informationHSV1716 Dose levels and Cohort size Dose level No of Patients HSV1716 Dosage 1* 3 to 6 1 ml of 1 x 10 5 infectious units HSV1716 per ml 2
Abstract and Schema: Description and Rationale: Pediatric high grade gliomas have a progressive initial course and high risk of relapse/ progression; making the 5-year overall survival rate 15-35% with
More informationWhat's New in Oncodermatopathology: Immunotherapy Reactions
What's New in Oncodermatopathology: Immunotherapy Reactions Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine Hospital of the University of Pennsylvania March
More informationThe emerging role of oncolytic virus therapy against cancer
Review Article Page 1 of 13 The emerging role of oncolytic virus therapy against cancer Luke Russell 1, Kah-Whye Peng 2 1 Vyriad, Rochester, MN, USA; 2 Mayo Clinic, Rochester, MN, USA Contributions: (I)
More informationEnhancing Anti-tumour Immunity with Oncolytic Viruses
Enhancing Anti-tumour Immunity with Oncolytic Viruses John Bell Ottawa Hospital Research Institute SUPPORTED BY: NATIONAL CANCER INSTITUTE OF CANADA/CCS THE TERRY FOX FOUNDATION PPG CANADIAN INSTITUTES
More informationOncolys BioPharma Inc.
The Fiscal Year ending December 2017 Financial Results Presentation February 9, 2018 Oncolys BioPharma Inc. (TSE mothers: 4588) Forward looking statements This presentation material may contain information
More informationMerck Oncology Overview. The Development of MSI-H Cancer Therapy. Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 2017
Merck Oncology Overview The Development of MSI-H Cancer Therapy Development of Anti-Cancer Drugs Forum Tokyo, Japan, 18, February 217 Andrew Joe, MD Executive Director, Late Stage Oncology Merck & Co.,
More informationmicrorna Therapeutics Heading Towards the Clinic
GENReports: Market & Tech Analysis microrna Therapeutics Heading Towards the Clinic > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us Topic Introduction and Scope
More informationFor personal use only. General Meeting 6 March 2014
General Meeting 6 March 2014 Disclaimer Certain statements made in this presentation are forward looking statements within the meaning of the safe harbour provisions of the United States Private Securities
More informationOncology Drug Development
Oncology Drug Development Presentation to BioShares Biotech Summit 2018 Queenstown, NZ 27 July 2018 ASX: KZA NASDAQ: KZIA Twitter: @KaziaTx Oncology remains the largest and fastest-growing sector of the
More informationCoxsackievirus A21: The basic facts
Phase II CALM Extension study: Intratumoral CAVATAK TM increases immune- cell infiltrates and up- regulates immune- checkpoint molecules in the microenvironment of lesions from advanced melanoma padents
More informationREQUEST FOR PROJECT TEAM MEMBER APPLICATION FOR CONDUCTING CLINICAL TRIALS USING TALIMOGENE LAHERPAREPVEC
REQUEST FOR PROJECT TEAM MEMBER APPLICATION FOR CONDUCTING CLINICAL TRIALS USING TALIMOGENE LAHERPAREPVEC The Cancer Therapy Evaluation Program (CTEP) is accepting Project Team Member Applications (PTMAs)
More informationOncolytic Virotherapy: Targeting Cancer Stem Cells
Oncolytic Virotherapy: Targeting Cancer Stem Cells Cancer Stem Cells (CSCs) or Cancer Initiating Cells (CICs) A consensus of five defining criteria has been established to affirm the existence of CICs:
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationArming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics. Charles Q. Morris MBChB MRCP(UK)
Arming the Oncolytic Virus Enadenotucirev to Develop Tumor-Localized Combination Immunotherapeutics Charles Q. Morris MBChB MRCP(UK) 1 Enadenotucirev (EnAd): Developed using directed evolution EnAd Start
More informationViralytics Limited (OTCQX: VRACY) VLA.AX - AUD ASX Buy
Joseph Pantginis, Ph.D., (646) 358-1907 jpantginis@roth.com Assaf Vestin, Ph.D., (646) 616-2785 avestin@roth.com Sales (800) 933-6830, Trading (800) 933-6820 COMPANY NOTE EQUITY RESEARCH April 14, 2015
More informationIMMUNOTHERAPY IMMUNOTHERAPY. CHI Immuno-oncology Summit Boston. 27 th August 2018
NEXT NEXT GENERATION GENERATION ONCOLYTIC ONCOLYTIC IMMUNOTHERAPY IMMUNOTHERAPY CHI Immuno-oncology Summit Boston 27 th August 2018 2 Safe harbor Any statements contained herein that are not statements
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationCancer Immunotherapy: Active Immunization Approaches
Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationCEL-SCI Corporation. NYSE American: CVM
CEL-SCI Corporation NYSE American: CVM Geert Kersten Chief Executive Officer 8229 Boone Boulevard, Suite 802 Vienna, VA 22182, USA Phone: (703) 506-9460 Forward Looking Statements This presentation includes
More informationJefferies Healthcare Conference, London, November 19-20, Elisabetta Castelli PhD Director Investor Relations
Jefferies Healthcare Conference, London, November 19-20, 2014 Elisabetta Castelli PhD Director Investor Relations SAFE HARBOR STATEMENT This presentation contains forward-looking statements. Although the
More informationNew Biological and Immunological Therapies for Cancer
New Biological and Immunological Therapies for Cancer Sant P. Chawla, M.D., FRACP The Sarcoma Oncology Center, Santa Monica CA 90403 7 th International Conference on Drug Discovery &Therapy 1 Promising
More informationClinical: Ipilimumab (MDX-010) Update and Next Steps
Clinical: Ipilimumab (MDX-010) Update and Next Steps Geoffrey M. Nichol, M.D., M.B.A. Senior Vice President, Product Development Medarex, Inc. R&D Day December 9, 2005 Ipilimumab: New Class of Cancer Therapy
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationAt the forefront of cancer immunotherapy. Investor Presentation January 2018
1 At the forefront of cancer immunotherapy Investor Presentation January 2018 Disclaimer Certain statements made in this presentation are forward looking statements within the meaning of the safe harbour
More information(generic name: ipilimumab) Injection 50 mg ( Yervoy ), a human anti-human CTLA-4 monoclonal. August 21, 2018
August 21, 2018 Opdivo Approved for Supplemental Applications for Expanded Indications of Malignant Pleural Mesothelioma and Adjuvant Treatment of Melanoma, Change in Dosage and Administration (D&A) of
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationInnovative Combination Strategies: Oncolytic and Systemic Therapy
Innovative Combination Strategies: Oncolytic and Systemic Therapy Sanjiv S. Agarwala, MD Professor of Medicine, Temple University Chief, Oncology & Hematology St. Luke s Cancer Center Bethlehem, PA, USA
More informationMoving Forward with Immunotherapies for Cancer
A Virtual Think Tank Executive Summary Moving Forward with Immunotherapies for Cancer By: Barbara Gilmore, Senior Consultant, Transformational Health, Frost & Sullivan Frost & Sullivan recently invited
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015
ZIOPHARM / Intrexon Graft-Versus-Host Disease Exclusive Channel Collaboration SEPTEMBER 28, 2015 1 Forward-looking Statements This presentation contains certain forward-looking information about ZIOPHARM
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationJEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018
1 JEFFERIES 2018 LONDON HEALTHCARE CONFERENCE NOVEMBER 15, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many
More informationPPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM
HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures
More informationIMMUNOTHERAPY FOR LUNG CANCER
IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide IMMUNOTHERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Lung Cancer Basics... 2 Immunotherapy... 3 FDA Approved Immunotherapies...
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationBAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY
BAVARIAN NORDIC BIO DEUTSCHLAND PRESENTATION OCTOBER 2014 CSE/OMX:BAVA, OTC:BVNRY This presentation includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which
More informationReviewers' comments: Reviewer #1 (Remarks to the Author):
Reviewers' comments: Reviewer #1 (Remarks to the Author): In the manuscript Rational Combination of CXCL11-Expressing Oncolytic Virus and PD-L1 Blockade Works Synergistically to Enhance Therapeutic Efficacy
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationSummary of the risk management plan (RMP) for Imlygic (talimogene laherparepvec)
EMA/713818/2015 Summary of the risk management plan (RMP) for Imlygic ( laherparepvec) This is a summary of the risk management plan (RMP) for Imlygic, which details the measures to be taken in order to
More informationMERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018
MERCK ONCOLOGY OVERVIEW AACR 2018 APRIL 16, 2018 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationTransforming patients lives through cellular immunotherapy. Next Generation Cellular Immunotherapy June 2017
Transforming patients lives through cellular immunotherapy Next Generation Cellular Immunotherapy June 2017 1 Overview of Cell Medica Mission: Transform the treatment of cancer with cellular immunotherapy
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More information